<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04563286</url>
  </required_header>
  <id_info>
    <org_study_id>IT08012020</org_study_id>
    <nct_id>NCT04563286</nct_id>
  </id_info>
  <brief_title>Patient-Reported Outcome Measures in Wild-Type and Variant Cardiac Transthyretin Amyloidosis</brief_title>
  <acronym>ITALY</acronym>
  <official_title>Patient-Reported Outcome Measures in Wild-Type and Variant Cardiac Transthyretin Amyloidosis: The Impact of Transthyretin Amyloidosis on Life qualitY (ITALY) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Messina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione Toscana Gabriele Monasterio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pavia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Università degli Studi di Ferrara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Careggi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Messina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Specific, standardized, comprehensive, universally accepted Patient-Reported Outcome Measures&#xD;
      (PROMs) are currently lacking for variant and wild-type cardiac amyloid transthyretin&#xD;
      amyloidosis (v-ATTR/wt-ATTR). Our goal is then to create two scores able to provide a&#xD;
      cumulative assessment of cardiac involvement, peripheral neuropathy (in v-ATTR), and&#xD;
      comorbidities, and their impact on the quality of life.&#xD;
&#xD;
      In the setting of a nationwide collaboration involving 5 main Italian referral centers for&#xD;
      this condition (in Ferrara, Florence, Pavia, Pisa and Messina), a panel will be created,&#xD;
      including experts of ATTR cardiomyopathy, neurologists, geriatricians, health management&#xD;
      specialists, as well as patients with either variant or wild-type ATTR cardiomyopathy (n=50).&#xD;
&#xD;
      The most clinically relevant domains for patients (such as physical limitations, symptoms,&#xD;
      self-efficacy and knowledge, social interference, quality of life, age-related issues, social&#xD;
      and family environment, frailty, comorbidities) will be identified. Two sets of 30 items (one&#xD;
      for variant and another for wild-type ATTR cardiomyopathy) will be created in collaboration&#xD;
      with patients. Questions will be formatted for gender neutrality, clarity, interpretability,&#xD;
      and possible foreign language translations. PROMs scores will be validated through&#xD;
      administration to around 250 consecutive outpatients. Score performance will be evaluated in&#xD;
      terms of internal consistency, response to clinical changes, comparison with conventional&#xD;
      clinical measures. The time needed for completion, the clarity of questions and the need for&#xD;
      assistance from a family caregiver will be evaluated.&#xD;
&#xD;
      This project will hopefully lead to the identification of disease-specific metrics that may&#xD;
      serve as a clinically meaningful outcome in cardiovascular research, patient management, and&#xD;
      quality assessment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2020</start_date>
  <completion_date type="Anticipated">June 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 22, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>reliability</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>internal consistency</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>responsiveness</measure>
    <time_frame>baseline to HF hospitalization (&lt;6 months)</time_frame>
    <description>changes in scores in response to clinical changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>validity of each domain</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>comparison of scores with other measures that quantify similar concepts, namely other score points, NYHA class, 6MWD, or objective measures of cardiac dysfunction, i.e. circulating levels of NT-proBNP and hs-TnT)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Transthyretin Amyloidosis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire on life quality</intervention_name>
    <description>Two sets of 30 PROMs questions will be created. The v-ATTR and wt-ATTR questionnaires will be critically evaluated by the whole panel, taking into account observations and feedback from patients. The 2 scores will be administered to consecutive patients evaluated at dedicated ambulatory clinics of the 4 Institutions. To confirm score reliability and responsiveness, 2 distinct patient cohorts will be recruited. The reliability cohort will be assembled to demonstrate the instrument's test-retest reliability. A second cohort of patients (responsiveness cohort) will be assembled to demonstrate the instrument's responsiveness to changes in clinical status. Patients experiencing a heart failure hospitalization within 6 months will enter the responsiveness cohort at the time of hospital admission.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cardiac ATTR amyloidosis, either biopsy proven or diagnosed according to the&#xD;
        algorithm for nonbiopsy diagnosis of ATTR cardiomyopathy (Gillmore et al., 2016), will be&#xD;
        evaluated.&#xD;
&#xD;
        PROMs for v-ATTR and wt-ATTR will be created in close collaboration with 50 patients&#xD;
        suffering from ATTR cardiomyopathy (see below), and will be validated on a cohort of 250&#xD;
        patients (i.e., 50 patients from each participating center; see below).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of cardiomyopathy due to ATTR amyloidosis, diagnosed by endomyocardial&#xD;
             biopsy or on the basis of the algorithm for the non-invasive diagnosis of cardiac ATTR&#xD;
             amyloidosis (Gillmore et al., 2016).&#xD;
&#xD;
          -  Clinical stability, defined as the lack of unscheduled hospitalizations and/or&#xD;
             significant changes in cardiac therapies from at least 1 month.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of informed consent.&#xD;
&#xD;
          -  Inability of understanding a written text in Italian.&#xD;
&#xD;
          -  Absence of the conditions of clinical stability, as defined above.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Università di Ferrara</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Rapezzi</last_name>
      <phone>+390532293111</phone>
      <email>claudio.rapezzi@unife.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Careggi Hospital</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Cappelli, MD</last_name>
      <phone>+39 055 794 9946</phone>
      <email>cappellifrancesco@inwind.it</email>
    </contact>
    <contact_backup>
      <last_name>MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Francesco Cappelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Federico Perfetto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università di Messina</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Di Bella</last_name>
      <phone>+393205506147</phone>
      <email>gianluca.dibella@unime.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università di Pavia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Palladini</last_name>
      <phone>+390382989898</phone>
      <email>giovanni.palladini@unipv.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Toscana Gabriele Monasterio (FTGM)</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Emdin</last_name>
      <phone>+393454744053</phone>
      <email>emdin@ftgm.it</email>
    </contact>
    <investigator>
      <last_name>Claudio Passino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 20, 2020</study_first_submitted>
  <study_first_submitted_qc>September 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>September 20, 2020</last_update_submitted>
  <last_update_submitted_qc>September 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Messina</investigator_affiliation>
    <investigator_full_name>Gianluca Di Bella</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>amyloidosis</keyword>
  <keyword>transthyretin</keyword>
  <keyword>quality of life</keyword>
  <keyword>score</keyword>
  <keyword>cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloid Neuropathies, Familial</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

